The recent merger of Symbio LLC and Dow Development Laboratories LLC with Proinnovera has given rise to Symbio Proinnovera, a dedicated dermatology-focused Contract Research Organization (CRO).
With a legacy spanning over two decades, the Symbio & Dow Group offers a comprehensive clinical trial CRO for dermatology. This is complemented by a business engaged in the pre-clinical formulation of topicals, providing clients with a continuum of dermatology and aesthetics services—from pre-clinical formulation work to subsequent clinical trial execution.
Founded 25 years ago, Proinnovera stands as a prominent European CRO in the dermatology clinical trial domain. As a full-service CRO, Proinnovera conducts clinical studies ranging from Phase I to IV, along with non-interventional and medical device studies. Proinnovera transforms study data into actionable insights for clients, facilitating accelerated decision-making and enhancing transparency and efficiency in clinical trial conduct.
Both companies have established themselves as market leaders among specialty dermatology CROs, boasting exceptional geographical coverage. The amalgamation of their strengths positions them to excel in meeting customer needs and expectations across all facets of research.
The newly forged organization will harness the collective expertise of two highly experienced teams with profound knowledge of the dermatology space, driving efficiencies and expediting progress in clinical research.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!